Nuvectra to Participate in Morgan Stanley Global Healthcare Conference

PLANO, Texas, Aug. 30, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Scott Drees, Chief Executive Officer, and Walter Berger, Chief Operating Officer & CFO, are scheduled to participate at the Morgan Stanley Global Healthcare Conference in New York, NY.

Event:       Morgan Stanley Global Healthcare Conference
Date:         Monday, September 11, 2017

The Company will be participating in one-on-one investor meetings at the conference and will not make a formal presentation. If interested in meeting with management, please reach out to Brian Johnston at [email protected], or your Morgan Stanley contact.

About Nuvectra Corporation

Nuvectra^TM is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita^® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic intractable pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other indications such as sacral neuromodulation (SNM) for the treatment of overactive bladder, and deep brain stimulation (DBS) for the treatment of Parkinson’s Disease. In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.

Company Contacts:		
Nuvectra Corporation		

Walter Berger, COO & CFO		
(214) 474-3102			
[email protected]		
				
Jennifer Armstrong, Media Relations
(214) 474-3110			
[email protected]	

Investor Contacts:
The Ruth Group		

Zack Kubow
(646) 536-7020		
[email protected]

Brian Johnston
(646) 536-7028
[email protected]